Etude de l'impact de la sur-expression de la partie C-terminale de LRRK2 mutée G2019S dans les neurones dopaminergiques de la substance noire.

Etude de l'impact de la sur-expression de la partie C-terminale de LRRK2 mutée G2019S dans les neurones dopaminergiques de la substance noire.

Les protéines alpha-synucléine (α-syn) et leucine-rich repeat kinase 2 (LRRK2) sont deux protéines ayant un rôle majeur dans la physiopathologie de la maladie de Parkinson (MP) et interviennent aussi bien dans les formes dites sporadiques que dans les formes familiales. La mutation G2019S du gène co...

Full description

Bibliographic Details
Main Author:	Cresto, Noemie
Other Authors:	Université Paris-Saclay (ComUE)
Language:	fr
Published:	2017
Subjects:	Lrrk2 Vecteurs viraux Toxicité Maladie de Parkinson Alpha-Synucléine Viral vector Toxicity Parkinson's disease Alpha-Synuclein
Online Access:	http://www.theses.fr/2017SACLS112

Similar Items

Etude de la coopération de l'alpha-synucléine et de LRRK2 dans les dysfonctions mitochondriales dans la Maladie de Parkinson
by: Gardier, Camille
Published: (2019)

LRRK2 and Protein Aggregation in Parkinson’s Disease: Insights From Animal Models
by: Dylan J. Dues, et al.
Published: (2020-07-01)

Phosphatases of α-synuclein, LRRK2 and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
by: Jean-Marc eTaymans, et al.
Published: (2014-11-01)

Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson’s Disease
by: Giulia Lamonaca, et al.
Published: (2020-04-01)

Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation
by: Michael Aagaard Andersen, et al.
Published: (2018-08-01)

Parkinson’s Disease-Related Genes and Lipid Alteration
by: Milena Fais, et al.
Published: (2021-07-01)

Editorial: Protein Degradation Pathways in Parkinson's Disease and Neurodegeneration
by: Mattia Volta, et al.
Published: (2020-07-01)

Post-transcriptional regulation of alpha-synuclein by leucine-rich repeat kinase 2 and micro-RNAs with implications for Parkinson's disease
by: Boon, Joon Ying
Published: (2016)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
by: Nour K. Majbour, et al.
Published: (2020-05-01)

A new hypothesis for Parkinson’s disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics
by: Julia Obergasteiger, et al.
Published: (2018-08-01)

Pathological Functions of LRRK2 in Parkinson’s Disease
by: Ga Ram Jeong, et al.
Published: (2020-11-01)

LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
by: Darren M. O’Hara, et al.
Published: (2020-06-01)

Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
by: Elisa Greggio, et al.
Published: (2006-08-01)

Regulation and targeting of enzymes mediating Parkinson’s disease pathogenesis: focus on Parkinson’s disease kinases, GTPases and ATPases
by: Jean-Marc eTaymans, et al.
Published: (2014-07-01)

Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons
by: Jason Schapansky, et al.
Published: (2018-03-01)

LRRK2-Related Parkinson’s Disease Due to Altered Endolysosomal Biology With Variable Lewy Body Pathology: A Hypothesis
by: Pilar Rivero-Ríos, et al.
Published: (2020-06-01)

Dexamethasone induces the expression of LRRK2 and α-synuclein, two genes that when mutated cause Parkinson’s disease in an autosomal dominant manner
by: Ji-Min Park, et al.
Published: (2013-09-01)

Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo
by: Souvarish Sarkar, et al.
Published: (2021-05-01)

Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils
by: Isabella Russo, et al.
Published: (2019-09-01)

Crosstalk between Lysosomes and Mitochondria in Parkinson's Disease
by: Nicoletta Plotegher, et al.
Published: (2017-12-01)

From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson’s Disease: Lessons From LRRK2
by: Andrea Mancini, et al.
Published: (2020-07-01)

Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson’s Disease Patients
by: Maximilianos Elkouris, et al.
Published: (2019-02-01)

The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease
by: Alexia Polissidis, et al.
Published: (2020-06-01)

LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation
by: Ye Zhao, et al.
Published: (2020-10-01)

PARKINSON’S DISEASE: ANIMAL MODELS AND DOPAMINERGIC CELL VULNERABILITY
by: Javier eBlesa, et al.
Published: (2014-12-01)

G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice
by: Salvatore Novello, et al.
Published: (2018-12-01)

Autophagy and LRRK2 in the Aging Brain
by: Federica Albanese, et al.
Published: (2019-12-01)

Crosstalk between presynaptic trafficking and autophagy in Parkinson's disease
by: Ping-Yue Pan, et al.
Published: (2019-02-01)

Elevated Levels of Cerebrospinal Fluid α-Synuclein Oligomers in Healthy Asymptomatic LRRK2 Mutation Carriers
by: Jan eAasly, et al.
Published: (2014-09-01)

The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease
by: Briana R. De Miranda, et al.
Published: (2021-06-01)

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons
by: Michael X. Henderson, et al.
Published: (2018-05-01)

Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice
by: Ye Zhao, et al.
Published: (2018-12-01)

Les Glycosaminoglycannes : nouveaux régulateurs de l’agrégation de l’α-synucléine et de l’apoptose dans un modèle cellulaire de la maladie de Parkinson
by: Lehri-Boufala, Sonia
Published: (2011)

Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics
by: Kaela Kelly, et al.
Published: (2020-08-01)

Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice
by: Dayne A Beccano-Kelly, et al.
Published: (2014-09-01)

Editorial: The Protein Alpha-Synuclein: Its Normal Role (in Neurons) and Its Role in Disease
by: Ruth G. Perez
Published: (2020-02-01)

FUNCTIONAL STUDY OF A NOVEL PROTEIN KINASE, LEUCINE-RICH REPEAT KINASE 2 (LRRK2), ASSOCIATED WITH PARKINSON’S DISEASE
by: Guo, Luxuan
Published: (2010)

LRRK2 G2019S, I2020T, R1441C GENE mutation analysis in patients with idiopathic Parkinsons in Turkey
by: Ahmet Adiguzel, et al.
Published: (2020-06-01)

Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases
by: Adamantios Mamais, et al.
Published: (2013-10-01)

Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice
by: Joanna A. Korecka, et al.
Published: (2020-09-01)